Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2010 1
2011 2
2012 1
2014 1
2017 1
2018 1
2019 1
2020 3
2021 4
2022 2
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
CRISPR-engineered T cells in patients with refractory cancer.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH. Stadtmauer EA, et al. Among authors: jadlowsky jk. Science. 2020 Feb 28;367(6481):eaba7365. doi: 10.1126/science.aba7365. Epub 2020 Feb 6. Science. 2020. PMID: 32029687 Clinical Trial.
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE; Prostate Cancer Cellular Therapy Program Investigators; Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB. Narayan V, et al. Nat Med. 2022 Apr;28(4):724-734. doi: 10.1038/s41591-022-01726-1. Epub 2022 Mar 21. Nat Med. 2022. PMID: 35314843 Free PMC article. Clinical Trial.
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, Davis MM, Xu J, Boesteanu AC, Barber-Rotenberg JS, Plesa G, Lacey SF, Jadlowsky JK, Siegel DL, Hammill DM, Cho-Park PF, Berger SL, Haas NB, Fraietta JA. Jung IY, et al. Among authors: jadlowsky jk. Sci Transl Med. 2022 Nov 9;14(670):eabn7336. doi: 10.1126/scitranslmed.abn7336. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350986 Free PMC article.
Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors.
Jung IY, Noguera-Ortega E, Bartoszek R, Collins SM, Williams E, Davis M, Jadlowsky JK, Plesa G, Siegel DL, Chew A, Levine BL, Berger SL, Moon EK, Albelda SM, Fraietta JA. Jung IY, et al. Among authors: jadlowsky jk. Cell Rep Med. 2023 Jun 20;4(6):101053. doi: 10.1016/j.xcrm.2023.101053. Epub 2023 May 23. Cell Rep Med. 2023. PMID: 37224816 Free PMC article.
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells.
Haas AR, Golden RJ, Litzky LA, Engels B, Zhao L, Xu F, Taraszka JA, Ramones M, Granda B, Chang WJ, Jadlowsky J, Shea KM, Runkle A, Chew A, Dowd E, Gonzalez V, Chen F, Liu X, Fang C, Jiang S, Davis MM, Sheppard NC, Zhao Y, Fraietta JA, Lacey SF, Plesa G, Melenhorst JJ, Mansfield K, Brogdon JL, Young RM, Albelda SM, June CH, Tanyi JL. Haas AR, et al. Among authors: jadlowsky j. Mol Ther. 2023 Aug 2;31(8):2309-2325. doi: 10.1016/j.ymthe.2023.06.006. Epub 2023 Jun 12. Mol Ther. 2023. PMID: 37312454
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, Nabavizadeh A, Jarocha D, Martins R, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz R, Jadlowsky JK, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Sun Y, Gladney W, Barrett D, Nasrallah MP, Hwang WT, Ming GL, Song H, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM. Bagley SJ, et al. Among authors: jadlowsky jk. Nat Med. 2024 Mar 13. doi: 10.1038/s41591-024-02893-z. Online ahead of print. Nat Med. 2024. PMID: 38480922
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL. Tebas P, et al. Among authors: jadlowsky jk. J Clin Invest. 2021 Apr 1;131(7):e144486. doi: 10.1172/JCI144486. J Clin Invest. 2021. PMID: 33571163 Free PMC article. Clinical Trial.
Long-term stability of clinical-grade lentiviral vectors for cell therapy.
Jadlowsky JK, Leskowitz R, McKenna S, Karar J, Ma Y, Dai A, Plesa G, Chen F, Alexander K, Petrella J, Gong N, Hwang WT, Farrelly O, Barber-Rotenberg J, Christensen S, Gonzalez VE, Chew A, Fraietta JA, June CH. Jadlowsky JK, et al. Mol Ther Methods Clin Dev. 2024 Jan 10;32(1):101186. doi: 10.1016/j.omtm.2024.101186. eCollection 2024 Mar 14. Mol Ther Methods Clin Dev. 2024. PMID: 38282894 Free PMC article.
24 results